1.	A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NO25026, 2009-012293-12, NCT01006980
2.	A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NP22657, NCT00949702
3.	A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO25653, NCT01253564
4.	A Study of RO5185426 in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML25597, NCT01248936
5.	Safety Study of PLX4032 in Patients With Solid Tumors Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PLX06-02, NCT00405587
6.	A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma Phase: Phase I Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: NP22676, NCT01001299
7.	A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NP25163, NCT01107418
8.	A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NP25158, NCT01164891